Liveome, an affiliate of botulinum toxin maker Medytox, said it won a patent for “engineered live biotherapeutics product (E-LBP),” a microbiome treatment development platform, in Japan.
The patent concerns E-LBP platform that precisely customizes microbiome technologies with specific therapeutic functions using gene editing. For example, it can enable accurate local delivery and secretion of target biologics, create new gene therapies to replace metabolic pathways, and maximize the microbe-host interaction effect.
Liveome’s E-LBP technology is a new type of treatment development platform that enhances the therapeutic effect based on leveraging the potential of existing microbiome treatments and increases the possibility of success in new drug development.
Outside Korea, the patent was approved in Japan for the first time. Liveome also applied for a patent in several other countries.
Liveome is applying the E-LBP platform to its pipeline drug, LIV001, a microbiome treatment targeting inflammatory bowel disease. It recently completed preclinical trials and completed clinical drug production in cooperation with global CDMOs such as AcuraBio in Australia and Quay Pharma in the U.K.
The company plans to start phase 1 of global clinical trials this year.
Liveome acquired domestic patents for two microbiome anticancer treatments in December 2022 and January 2023. These are patents for candidate anticancer drugs developed through the natural live biotherapeutic product (N-LBP) platform, a specialized screening platform for disease-specific microbiomes.